ArticleEuropean journal of medical research2026
Evaluating the role of serum IL1R2 as a biomarker for diagnosis and prognostic stratification in sepsis.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aimed to identify novel sepsis biomarkers by evaluating serum interleukin-1 receptor type 2 (IL1R2) for its diagnostic and prognostic utility, in light of the limitations of current markers like PCT and CRP.
methodsA single-center retrospective analysis was conducted involving 55 sepsis patients and 42 non-sepsis controls. Serum IL1R2 levels, measured via ELISA within 24 h of admission, were compared against clinical data, including SOFA scores, 28-day mortality, and laboratory parameters (PCT, CRP). Diagnostic performance was assessed using ROC curve analysis, while prognostic utility was determined via Kaplan-Meier analysis. A cecal ligation and puncture (CLP) was used to track IL1R2 dynamics over time.
resultsSepsis patients exhibited significantly elevated serum IL1R2 levels compared to controls. IL1R2 demonstrated strong diagnostic power (AUC = 0.908), outperforming PCT and CRP. Furthermore, higher IL1R2 levels correlated with increased SOFA scores and predicted poorer 28-day survival. In the CLP model, serum IL1R2 rose within 4 h post-sepsis, peaked within 24 h, returned to baseline by day 3, and fell below normal by day 7.
conclusionSerum IL1R2 is a promising biomarker, offering a superior ability to correlate with disease severity and predict 28-day mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.